New cholera vaccine trial aims to protect families in High-Risk areas
NCT ID NCT07509047
First seen Apr 05, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests a new cholera vaccine (OSP:rTTHc) in 390 healthy adults and children aged 1 to 45 in regions where cholera is common. Researchers will check how well the vaccine triggers an immune response and if it is safe, comparing one or two doses with or without an adjuvant. The goal is to find the best dosing schedule to protect against cholera.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KAVI-Institute of Clinical Research, University
RECRUITINGNairobi, Kenyatta National Hospital Complex, 19676, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.